KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Shares Issued (2016 - 2025)

Ionis Pharmaceuticals (IONS) has 16 years of Shares Issued data on record, last reported at $107.8 million in Q4 2025.

  • For Q4 2025, Shares Issued fell 76.35% year-over-year to $107.8 million; the TTM value through Dec 2025 reached $192.6 million, down 80.17%, while the annual FY2025 figure was $192.6 million, 60.62% down from the prior year.
  • Shares Issued reached $107.8 million in Q4 2025 per IONS's latest filing, up from $81.3 million in the prior quarter.
  • Across five years, Shares Issued topped out at $489.1 million in Q3 2024 and bottomed at -$78.2 million in Q4 2021.
  • Average Shares Issued over 5 years is $57.9 million, with a median of $2.6 million recorded in 2023.
  • Peak YoY movement for Shares Issued: tumbled 2630.61% in 2023, then surged 13012.6% in 2024.
  • A 5-year view of Shares Issued shows it stood at -$78.2 million in 2021, then skyrocketed by 100.44% to $343000.0 in 2022, then crashed by 2630.61% to -$8.7 million in 2023, then skyrocketed by 5352.45% to $455.9 million in 2024, then plummeted by 76.35% to $107.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Issued were $107.8 million in Q4 2025, $81.3 million in Q3 2025, and $1.3 million in Q2 2025.